- Home
- LSBK vs AVTX Comparison
LSBK vs AVTX Comparison
Compare LSBK & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- AVTX
- Stock Information
- Founded
- LSBK 1891
- AVTX 2011
- Country
- LSBK United States
- AVTX United States
- Employees
- LSBK N/A
- AVTX N/A
- Industry
- LSBK Savings Institutions
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- AVTX Health Care
- Exchange
- LSBK Nasdaq
- AVTX Nasdaq
- Market Cap
- LSBK 76.9M
- AVTX 90.9M
- IPO Year
- LSBK 2006
- AVTX 2015
- Fundamental
- Price
- LSBK $13.51
- AVTX $12.58
- Analyst Decision
- LSBK
- AVTX Buy
- Analyst Count
- LSBK 0
- AVTX 2
- Target Price
- LSBK N/A
- AVTX $35.00
- AVG Volume (30 Days)
- LSBK 1.2K
- AVTX 64.4K
- Earning Date
- LSBK 10-23-2024
- AVTX 11-07-2024
- Dividend Yield
- LSBK 5.33%
- AVTX N/A
- EPS Growth
- LSBK N/A
- AVTX N/A
- EPS
- LSBK 0.75
- AVTX N/A
- Revenue
- LSBK $25,338,000.00
- AVTX $820,000.00
- Revenue This Year
- LSBK N/A
- AVTX N/A
- Revenue Next Year
- LSBK N/A
- AVTX N/A
- P/E Ratio
- LSBK $18.10
- AVTX N/A
- Revenue Growth
- LSBK N/A
- AVTX N/A
- 52 Week Low
- LSBK $10.12
- AVTX $3.95
- 52 Week High
- LSBK $14.21
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- LSBK 49.26
- AVTX 52.17
- Support Level
- LSBK $13.38
- AVTX $12.00
- Resistance Level
- LSBK $13.90
- AVTX $13.59
- Average True Range (ATR)
- LSBK 0.15
- AVTX 0.96
- MACD
- LSBK -0.02
- AVTX -0.15
- Stochastic Oscillator
- LSBK 37.14
- AVTX 33.52
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).